Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
Cheaper versions of the “gamechanger” HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, manufacturer Gilead Sciences has announced.
However, campaigners said the deal “abandons” many countries with a high HIV burden, particularly in Latin America, and urged transparency over exact pricing.
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says
European journalists targeted with Paragon Solutions spyware, say researchers